Ac-LKKTETQ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
== Structure == The first 3D structure of hCTR1 was based on electron crystallography, revealing that hCTR1 has a homotrimeric channel-like architecture. It consists of three indentical monomers, the monomers oligomerize through their transmembrane regions, and a monomer of hCtr1 has these characteristics:
This suggests FEN1 suppresses H-DNA-induced mutagenesis in a replication-dependent manner. H-DNA has been implicated in human cancer etiology because of the prevalence of H-DNA-forming sequences near translocation breakpoints in cancer genomes. Replication-mediated nuclease activity with H-DNA highlights another way H-DNA-induced mutagenesis and lead to cancer growth.
Sequence homology is the biological homology between DNA, RNA, or protein sequences, defined in terms of shared ancestry in the evolutionary history of life. Two segments of DNA can have shared ancestry because of three phenomena: either a speciation event (orthologs), or a duplication event (paralogs), or else a horizontal (or lateral) gene transfer event (xenologs). Homology among DNA, RNA, or proteins is typically inferred from their nucleotide or amino acid sequence similarity. Significant similarity is strong evidence that two sequences are related by evolutionary changes from a common ancestral sequence. Alignments of multiple sequences are used to indicate which regions of each sequence are homologous.
=== Ultraviolet (UV) inactivation === UV rays can damage the DNA of living organisms by creating nucleic acid dimers. However, the damages are usually not important due to low penetration of UVs through living tissues. UV rays can be used, however, to inactivate viruses since virus particules are small and the UV rays can reach the genetic material, inducing the dimerisation of nucleic acids. Once the DNA dimerised, the virus particules cannot replicate their genetic material which prevent them from spreading. UV light in combination with riboflavin has been shown to be effective in reducing pathogens in blood transfusion products. Riboflavin and UV light damages the nucleic acids in viruses, bacteria, parasites, and donor white blood cells rendering them unable to replicate and cause disease.
Sources: en.wikipedia.org
Meitnerium is a synthetic chemical element; it has symbol Mt and atomic number 109. It is an extremely radioactive synthetic element (not naturally occurring, but can be created in a laboratory). The most stable known isotope, meitnerium-278, has a half-life of 4.5 seconds, although the unconfirmed meitnerium-282 may have a longer half-life of 67 seconds. The element was first synthesized in August 1982 by the GSI Helmholtz Centre for Heavy Ion Research near Darmstadt, Germany, and it was named after the Austrian-Swedish nuclear physicist Lise Meitner in 1997. In the periodic table, meitnerium is a d-block transactinide element. It is a member of the 7th period and is placed in the group 9 elements, although no chemical experiments have yet been carried out to confirm that it behaves as the heavier homologue to iridium in group 9 as the seventh member of the 6d series of transition metals. Meitnerium is calculated to have properties similar to its lighter homologues, cobalt, rhodium, and iridium.
Thomas also spent part of his summer holidays with Jim's sister, Rachel Jones, at neighbouring Pentrewyman farm, where he spent his time riding Prince the cart horse, chasing pheasants and fishing for trout. All these relatives were bilingual, and many worshipped at Smyrna chapel in Llangain where the services were always in Welsh, including Sunday School which Thomas sometimes attended. There is also an account of the young Thomas being taught how to swear in Welsh. His schoolboy friends recalled that "It was all Welsh—and the children played in Welsh...he couldn't speak English when he stopped at Fernhill...in all his surroundings, everybody else spoke Welsh..." At the 1921 census, 95% of residents in the two parishes around Fernhill were Welsh speakers. Across the whole peninsula, 13%—more than 200 people—spoke only Welsh. A few fields south of Fernhill lay Blaencwm, a pair of stone cottages to which his mother's Swansea siblings had retired, and with whom the young Thomas and his sister, Nancy, would sometimes stay. A couple of miles down the road from Blaencwm is the village of Llansteffan, where Thomas used to holiday at Rose Cottage with another Welsh-speaking aunt, Anne Williams, his mother's half-sister who had married into local gentry. Anne's daughter, Doris, married a dentist, Randy Fulleylove. The young Dylan also holidayed with them in Abergavenny, where Fulleylove had his practice. Thomas's paternal grandparents, Anne and Evan Thomas, lived at The Poplars in Johnstown, just outside Carmarthen. Anne was the daughter of William Lewis, a gardener in the town.
== Military campaigns in Syria and Jazira == Ubayd Allah fought for Marwan and his tribal allies against the Qaysi tribes led by al-Dahhak ibn Qays al-Fihri, the governor of Damascus, at the Battle of Marj Rahit in August 684. The Qays were routed and al-Dahhak killed. Ubayd Allah was put in command of Marwan's army which, during Marj Rahit, consisted of 6,000 men from a handful of loyalist tribes. According to Kennedy, Ubayd Allah "clearly intended to rebuild the Syrian army which had served Mu'awiya and Yazid I so well". In the aftermath of Marj Rahit, Ubayd Allah oversaw campaigns against rebel Qaysi tribes for Marwan and his son and successor Abd al-Malik (r. 685–705) in the Jazira. However, Marwan's forces were too little to assert Umayyad rule throughout the caliphate. Thus, Ubayd Allah expanded recruitment to include various Qaysi tribes. He placed Husayn ibn Numayr al-Sakuni of Kindah as his second-in-command, and Shurahbil ibn Dhi'l Kala' of Himyar, Adham ibn Muhriz of Bahila, Rabi'a ibn al-Mukhariq of Banu Ghani and Jabala ibn Abd Allah of Khath'am as deputy commanders. Other than Husayn ibn Numayr, all of the commanders were either Qaysi or had earlier supported al-Dahhak against Marwan. In January 685, as Ubayd Allah was in Manbij preparing for the Umayyad reconquest of Iraq, Husayn ibn Numayr defeated the pro-Alid Penitents at the Battle of Ayn al-Warda. Ubayd Allah had been promised by Marwan the governorship over all of the lands he could conquer from the Alids and Ibn al-Zubayr, and he may have been sanctioned to plunder Kufa.
== History == The nitrophenyl ethers are a well-known class of herbicides, the oldest member of which was nitrofen, invented by Rohm & Haas and first registered for sale in 1964. This area of chemistry became very competitive, with the Mobil Oil Corporation's filing in 1969 and grant in 1974 of a patent to the structural analog with a COOCH3 group adjacent to the nitro group of nitrofen. This product, bifenox, was launched with the brand name Mowdown in 1981. Meanwhile, Rohm & Haas introduced acifluorfen (as its sodium salt with brand name Blazer) in 1980, having developed it under the code number RH-6201. It had much improved properties including a wider spectrum of herbicidal effect and good safety to soybean crops. The first patent for the material was published in December 1975, although an earlier Belgian patent published in September 1973 had described related chemistry.
Hypusine is an uncommon amino acid found in all eukaryotes and in some archaea, but not in bacteria. The only known proteins containing the hypusine residue is eukaryotic translation initiation factor 5A (eIF-5A) and the archaeal homolog aIF5A. In humans, two isoforms of eIF-5A have been described: eIF5A-1 and eIF5A-2. They are encoded by two distinct genes EIF5A and EIF5A2. The protein is involved in protein biosynthesis and promotes the formation of the first peptide bond. The region surrounding the hypusine residue is highly conserved and is essential to the function of eIF5A. Thus, hypusine and eIF-5A appear to be vital for the viability and proliferation of eukaryotic cells. Hypusine is formed in eIF-5A by post-translational modification of one of the lysyl residues. Two reactions and two enzymes are involved:
Sources: en.wikipedia.org
Representative James Talarico legislative website Talarico for Texas U.S. Senate campaign website Financial information (federal office) at the Federal Election Commission Profile at Vote Smart Appearances on C-SPAN
== Relationship to docking methods == The field of protein–protein interaction prediction is closely related to the field of protein–protein docking, which attempts to use geometric and steric considerations to fit two proteins of known structure into a bound complex. This is a useful mode of inquiry in cases where both proteins in the pair have known structures and are known (or at least strongly suspected) to interact, but since so many proteins do not have experimentally determined structures, sequence-based interaction prediction methods are especially useful in conjunction with experimental studies of an organism's interactome.
After much deliberation, we've made the difficult decision to close this location. We are incredibly grateful for the many years of great times, cold beer, hot wings, and unforgettable memories shared here. Thank you to our guests, team members, and community for the support over the years.
The pentastack is a hazardous five-drug mixture discussed in online looksmaxxing communities that combines powerful stimulants and severe central nervous system depressants. It consists of: Adderall, dextromethorphan, pregabalin, ketamine and BDO (1,4-Butanediol). It has been compared to the date rape drug Rohypnol by Vanity Fair.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.